Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences Trading Down 3.8 %

Shares of NASDAQ:EXAS opened at $39.56 on Thursday. The stock has a 50 day moving average price of $43.57 and a 200 day moving average price of $57.38. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.70. Exact Sciences has a 52-week low of $35.34 and a 52-week high of $108.99.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Cowen reduced their price objective on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 3rd. Piper Sandler dropped their target price on Exact Sciences from $50.00 to $40.00 in a report on Wednesday. Citigroup dropped their target price on Exact Sciences from $65.00 to $50.00 and set a "neutral" rating for the company in a report on Wednesday, August 3rd. Cowen dropped their price objective on Exact Sciences from $83.00 to $67.00 and set an "outperform" rating for the company in a report on Wednesday, August 3rd. Finally, Evercore ISI raised their target price on Exact Sciences to $65.00 in a research note on Tuesday, August 9th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $70.23.

Insiders Place Their Bets

In other news, Director Katherine S. Zanotti sold 4,608 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the sale, the director now owns 60,318 shares in the company, valued at approximately $2,722,754.52. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Katherine S. Zanotti sold 4,608 shares of the company's stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total value of $208,005.12. Following the transaction, the director now directly owns 60,318 shares of the company's stock, valued at approximately $2,722,754.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm's stock in a transaction dated Thursday, June 30th. The shares were sold at an average price of $40.13, for a total value of $43,581.18. Following the sale, the director now owns 60,318 shares in the company, valued at $2,420,561.34. The disclosure for this sale can be found here. Insiders sold a total of 5,701 shares of company stock worth $251,872 over the last 90 days. Company insiders own 1.30% of the company's stock.